Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Oncolytics Biotech Inc.NASDAQ: ONCY

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month revenue was CA$0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0— QoQ
Last fiscal yearDec 2025
CA$0— YoY
LTMMar 2026
CA$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

CAD · from the income statement

Latest · FY2025
0 CAD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
ONCY Competitors
Revenue for ONCY and competitors
Company Period LTM YoY 3-year CAGR
MGNXMacroGenics, Inc.LTM Mar 2026$157.08M USD+3.1%-0.1%
COYACoya Therapeutics, Inc.LTM Mar 2026$7.94M USD+115.4%—
SRZNSurrozen, Inc.LTM Mar 2026$7.49M USD-35.6%-34.7%
CLNNClene Inc.LTM Mar 2026$134K USD-61.7%-24.9%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$0 CAD——
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD——
WHWKWhitehawk Therapeutics IncLTM Mar 2026$0 USD-100.0%-22.3%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%—
TILInstil Bio, Inc.LTM Mar 2026$0 USD——
Peer median (excluding ONCY) —-48.7%-23.6%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue360.58K301.11K298.59K87K70K
Gross Profit(360.58K)(301.11K)(298.59K)(87K)(70K)
Gross Margin—————
Research & Development10.31M11.85M13.12M21.65M18.27M
Selling, General & Admin10.26M8.53M11.62M13.34M21.15M
Operating Expenses20.56M20.38M24.74M34.98M39.41M
Depreciation & Amortization360.58K301.11K298.59K102K96.05K
EBITDA(20.58M)(18.71M)(20.19M)(34.88M)(39.41M)
EBITDA Margin—————
Operating Income(20.93M)(20.68M)(25.04M)(34.98M)(39.41M)
Operating Margin—————
Interest Income99K528K1.33M1.2M529.64K
Interest Expense00000
Other Income / Expenses(15.88K)1.67M4.55M3.4M61.75K
Income Before Tax(20.94M)(19.01M)(20.49M)(31.58M)(39.35M)
Pre-Tax Margin—————
Income Tax Expense39.42K64.52K71.87K130K108.4K
Net Income(20.98M)(19.08M)(20.56M)(31.71M)(39.46M)
Net Margin—————
EPS (Basic)(0.49)(0.44)(0.41)(0.41)(0.41)
EPS (Diluted)(0.49)(0.44)(0.41)(0.41)(0.41)
Weighted Avg Shares53.51M58.03M67.62M76.48M95.86M
Weighted Avg Shares (Diluted)53.51M58.03M67.62M76.48M95.86M

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.